Head and Neck Cancer Squamous Cell Clinical Trial
Official title:
A Phase II Study, Multicenter, to Evaluate the Efficacy and Safety of the Combination of Reirradiation - Erbitux in Subjects Previously Irradiated and With a Local Recurrent Inoperable Squamous Cell Cancer of the Head and Neck
The purpose of this study is to investigate in patients with cancer of the throat and
recurrent inoperable a different modality treatment consisting of radiation continuously for
5 weeks and half associated with a drug directed against a receptor on cell surfaces cancer,
called Erbitux ®.
The investigators hope with this shorter treatment (1.5 weeks less than the usual treatment)
to improve the antitumor efficacy without additional toxic side effects.
We hope with this treatment improved antitumor efficacy without additional toxic side
effects, while being shorter than 1.5 weeks of standard therapy. But this is an hypothesis we
can not meet the current state of knowledge, which justifies this study.
The main hypothesis is that this combination of reirradiation and Cetuximab give a relative
gain of 15% complete response rate.
;